The effects of intravenous propofol administration for general anesthesia in cesarean deliveries on maternal and infant health will be evaluated in relation to maternal and umbilical cord blood propofol levels.

After the ethics committee approval was obtained, volunteers who met the criteria for inclusion in the study were included in the study after obtaining their written permission. After the patients were taken to the operating room, IV catheterization was achieved after CTA, TA and sPO2 monitoring, and the patient was intubated 2 minutes after induction of propfol at 3 mg/kg and rocuronium at 0.6 mg/kg. After the baby was born, an intravenous blood sample was taken from the umbilical cord and the mother simultaneously. After the venous blood samples were obtained as 3 μL, the serum samples obtained by centrifugation as standard were portioned in equal volume to 500 μL Eppendorf tubes and stored at -80°C. After this pre-treatment, propofol was subjected to measurement tests with HPLC, and the collected data were added

Inclusion Criteria:

• Being pregnant in ASA category 1-2
• >39 weeks of healthy pregnancy
• >28 weeks complicated pregnancy
• Cesarean delivery with or without action
• Providing induction of general anesthesia with intravenous propofol

Exclusion Criteria:

• Pregnant women under the age of 18,
• Those who have stillbirth,
• Severe chronic kidney and liver disease,
• Neurological disease
• Those with other systemic diseases

female